Q-omics provides the consensus-scored FSCN3 profile across patient tissues and cancer cell-line models. FSCN3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FSCN3 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FSCN3 RNA expression shows 15,366 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, KIRC, and KIRP as cancer lineages where FSCN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FSCN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FSCN3 survival associations across molecular data types. FSCN3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FSCN3 RNA expression–survival associations across cancer types. High FSCN3 expression shows unfavorable associations in ACC, MESO, LGG, KICH, BRCA and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify ACC as the clearest survival context for FSCN3 RNA expression.
This table summarizes FSCN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FSCN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FSCN3 shows lower tumor expression in THCA, BRCA, KICH and LUAD and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher FSCN3 RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p < 0.001).
This table shows molecular features associated with FSCN3 in patient tissues and cancer cell lines. In patient samples, FSCN3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, FSCN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
